Mandel Silvia A, Amit Tamar, Weinreb Orly, Reznichenko Lydia, Youdim Moussa B H
Eve Topf Center for Neurodegenerative Diseases Research and Department of Pharmacology, Faculty of Medicine, Technion, Haifa, Israel.
CNS Neurosci Ther. 2008 Winter;14(4):352-65. doi: 10.1111/j.1755-5949.2008.00060.x.
Current therapeutic approaches for Alzheimer and Parkinson disease (AD and PD, respectively) are merely symptomatic, intended for the treatment of symptoms, but offer only partial benefit, without any disease-modifying activity. Novel promising strategies suggest the use of antiinflammatory drugs, antioxidants, iron-complexing molecules, neurotrophic factor delivery, inhibitors of the amyloid precursor protein (APP)-processing secretases, gamma and beta (that generate the amyloid-beta peptides, Abeta), anti-Abeta aggregation molecules, the interference with lipid cholesterol metabolism and naturally occurring plant flavonoids to potentially reverse the course of the diseases. Human epidemiological and new animal data suggest that tea drinking may decrease the incidence of dementia, AD, and PD. In particular, its main catechin polyphenol constituent (-)-epigallocatechin-3-gallate (EGCG) has been shown to exert neuroprotective/neurorescue activities in a wide array of cellular and animal models of neurological disorders. In the current article, we review the literature on the impact of the multimodal activities of green tea polyphenols and their neuroprotective effect on AD and PD.
目前针对阿尔茨海默病和帕金森病(分别简称为AD和PD)的治疗方法仅仅是对症治疗,旨在缓解症状,但只能带来部分益处,并无任何改变疾病进程的作用。一些新的、有前景的策略包括使用抗炎药物、抗氧化剂、铁络合分子、神经营养因子递送、淀粉样前体蛋白(APP)加工分泌酶(γ和β,它们可生成β淀粉样肽,即Aβ)的抑制剂、抗Aβ聚集分子、干扰脂质胆固醇代谢以及天然存在的植物黄酮类化合物,以期潜在地逆转疾病进程。人类流行病学研究和新的动物实验数据表明,饮茶可能会降低痴呆症、AD和PD的发病率。特别是,其主要的儿茶素多酚成分(-)-表没食子儿茶素-3-没食子酸酯(EGCG)已被证明在多种神经疾病的细胞和动物模型中具有神经保护/神经挽救活性。在本文中,我们综述了关于绿茶多酚多模式活性及其对AD和PD神经保护作用的文献。